Tags : Terrosa

Biosimilars

Daewon Pharmaceutical Launches its Terrosa (biosimilar, teriparatide) to Treat Osteoporosis

Shots: Terrosa is a parathyroid hormone (PTH) gene recombination candidate originally developed by Richter-Helm Biotec to treat osteoporosis in men and postmenopausal women including those at high risk of fracture. Additionally, Terrosa has completed its P-I and P-III trials in EU and Japan has shown an increase in bone density in the spine, femur, and […]Read More

Insights+

Insights+ Key Biosimilars Events of August 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space […]Read More

Biosimilars

Gedeon Richter Launches Terrosa (biosimilar, teriparatide) in Europe

Shots: Richter has launched Terrosa, a biosimilar to Eli Lilly’s Forsteo approved for osteoporosis in postmenopausal women and in men at high risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture Richter launched Terrosa through its affiliates in Europe following the patent […]Read More